Objective: Our aim is to determine the lifetime and past-year prevalence estimates of multiple Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-5) substance use disorders (SUDs) among U.S. adults.
Methods: The 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions featured in-person interviews with a nationally representative sample of adults aged 18 and older.
Results: The majority of past-year nonalcohol DSM-5 SUDs had at least 1 other co-occurring past-year SUD, ranging from 56.8% (SE = 3.4) for past-year prescription opioid use disorder to 97.5% (SE = 2.7) for past-year hallucinogen use disorder. In contrast, only 15.0% (SE = 0.6) of past-year alcohol use disorders had a co-occurring past-year SUD. The odds of past-year multiple SUDs were greater among males, younger adults, African-Americans, and those with mood, personality, posttraumatic stress, or multiple psychiatric disorders.
Conclusions: Assessment, diagnosis, and treatment often focus on individual substance-specific SUDs rather than multiple SUDs, despite evidence for substantial rates of polysubstance use in clinical and epidemiological studies. There are notable differences in the prevalence of multiple SUDs between alcohol use disorders and other nonalcohol SUDs that have important clinical implications; for example, multiple SUDs are more persistent than individual SUDs. These findings suggest that clinical assessment and diagnosis should screen for multiple SUDs, especially among adults with nonalcohol DSM-5 SUDs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898189 | PMC |
http://dx.doi.org/10.1002/hup.2625 | DOI Listing |
Metab Brain Dis
January 2025
Florey Institute of Neuroscience & Mental Health, Parkville, VIC, Australia.
Substance use disorders (SUDs) pose a significant global health challenge, with relapse being a major obstacle in achieving successful treatment outcomes. In recent years, drug delivery strategies have emerged as promising tools to improve treatment efficacy and patient compliance in the context of SUD. Here we explore a diverse range of drug delivery strategies that have been investigated for addressing relapse behavior in SUD.
View Article and Find Full Text PDFJ Addict Med
November 2024
From the Center for the Study of Drugs, Alcohol, Smoking, and Health, University of Michigan, Ann Arbor, MI (EP, RJE-P, TSS, CWE, VVM, SEM); Institute for Social Research, University of Michigan, Ann Arbor, MI (RJE-P, CWE, SEM); Department of Psychology, Texas State University, San Marcos, TX (TSS); Department of Psychiatry, University of Michigan, Ann Arbor, MI (VVM); and Lighthouse Institute at Chestnut Health Systems, Eugene, OR (TKD).
Objectives: Most US treatment and recovery services are abstinence-based. However, many people in recovery from an alcohol or other drug (AOD) use problem do not abstain completely. This study estimated the prevalence of and characteristics associated with nonabstinence among US adults in recovery.
View Article and Find Full Text PDFJ Gen Intern Med
January 2025
Section of Addiction Medicine in Division of General Internal Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
Background: Hospitalization is a "reachable" moment to engage people in addiction care. Addiction consult services (ACSs) have been shown to improve outcomes for hospitalized patients with substance use disorders (SUDs). Despite this, most hospital systems do not provide hospital-based addiction care or have an ACS.
View Article and Find Full Text PDFCureus
December 2024
Osteopathic Medicine/Internal Medicine, A.T. Still University, Mesa, USA.
Substance use disorders (SUDs) represent one of the leading causes of preventable death in the setting of overdose and comorbidities leading to mortality. A multi-database literature search limited to peer-reviewed articles within the last 10 years was conducted to compare treatment modalities used to treat SUDs. This literature review aims to provide a concise yet comprehensive summary of the various treatment modalities that exist to address these disorders in clinical practice.
View Article and Find Full Text PDFCurr Addict Rep
February 2024
Schar School of Policy and Government, George Mason University, 3351 Fairfax Drive, Arlington, VA 22201, USA.
Purpose Of Review: The purpose of this review is to investigate the use of digital health technologies and/or digital therapeutics (DTx) products in the treatment of substance use disorders (SUDs) in the general population and among criminal justice-involved individuals.
Recent Findings: Despite an expanding evidence base, only three SUD DTxs have received federal regulatory approval. Across studies, DTx products have proven successful in engaging patients in SUD treatment and reducing healthcare costs and resource utilizations.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!